Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HNF4A | P41235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6842022 | 0.79 | BCAT2 (0.63) | BCAT2MEN1GAAKMT2AALDH1A1 | |
| Carbamic Acid SCHEMBL474690 | 0.78 | CASP1 (0.42) | BCAT2MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL6135309 | 0.78 | GPR55 (0.39) | BCAT2ALDH1A1NPC1RAB9ABRD4 | |
| SCHEMBL11776499 | 0.77 | BCAT2 (0.53) | BCAT2GAAALDH1A1NPC1RAB9A | |
| SCHEMBL2200428 | 0.76 | GPR55 (0.38) | BCAT2ALDH1A1NPC1RAB9ABRD4 | |
| SCHEMBL58582 | 0.75 | RAB9A (0.36) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL8998624 | 0.75 | RAB9A (0.39) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL29929296 | 0.75 | HSD17B10 (0.39) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL673262 | 0.75 | BCAT2 (0.50) | BCAT2ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL27874785 | 0.73 | PARP1 (0.44) | NPC1RAB9APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150190504-A1 | WOUND HEALING | KINETIC CONCEPTS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8957076-B2 | Wound healing | SYSTAGENIX WOUND MANAGEMENT (US), INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8063052-B2 | Wound healing | SYSTAGENIX WOUND MANAGEMENT (US), INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100099622-A1 | WOUND HEALING | SYSTAGENIX WOUND MANAGEMENT (US), INC. (US) | 2010-04-22 | — | — | US | disclosed |
| CN-101563106-A | Combination of nmda- receptor ligand and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-10-21 | — | — | CN | disclosed |
| CN-101500611-A | Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-08-05 | — | — | CN | disclosed |
| US-20090170910-A1 | WOUND HEALING | KCI USA, INC. | 2009-07-02 | — | — | US | disclosed |
| CN-101133034-A | Substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their preparation and use in medicaments | ESTEVE LABOR DR (ES) | 2008-02-27 | — | — | CN | disclosed |
| EP-1786409-A1 | WOUND HEALING | ETHICON, INC. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006028836-A1 | WOUND HEALING | ETHICON, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | BCAT2 1158/4885MEN1 4379/4885GAA 3909/4885 |
| US-20100099622-A1 | WOUND HEALING | MAPK1, MAPK3, MAPK4 | BCAT2 2070/4885MEN1 4786/4885GAA 4803/4885 |
| US-20090170910-A1 | WOUND HEALING | MAPK1, MAPK3, MAPK4 | BCAT2 2070/4885MEN1 4786/4885GAA 4803/4885 |
| US-20150190504-A1 | WOUND HEALING | MAPK1, MAPK3, MAPK4 | BCAT2 2070/4885MEN1 4786/4885GAA 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.